Cargando…

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

XPO1 (exportin1) mediates nuclear export of proteins and RNAs and is frequently overexpressed in cancers. In this study, we show that the orally bioavailable XPO1 inhibitor KPT-330 reduced Mcl-1 protein level, by which it synergized with Bcl-xL inhibitor A-1331852 to induce apoptosis in cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Zhi-Chuan, Liu, Ji-Wei, Yang, Can, Zhao, Miao, Xiong, Zhi-Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529444/ https://www.ncbi.nlm.nih.gov/pubmed/31113936 http://dx.doi.org/10.1038/s41419-019-1627-9

Ejemplares similares

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
por: Zhao, Cheng, et al.
Publicado: (2022)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway
por: Liu, Shuhan, et al.
Publicado: (2022)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
por: Huang, Tianlu, et al.
Publicado: (2019)

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation
por: Opydo, Małgorzata, et al.
Publicado: (2023)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
por: Senichkin, Viacheslav V., et al.
Publicado: (2021)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
por: Nie, Danian, et al.
Publicado: (2018)

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
por: Wang, Bin, et al.
Publicado: (2014)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
por: Alcon, Clara, et al.
Publicado: (2021)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
por: Peddaboina, Chander, et al.
Publicado: (2012)

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2022)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
por: Zhao, Tianming, et al.
Publicado: (2023)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells
por: Zhang, Yu, et al.
Publicado: (2016)

The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance
por: Fitzgerald, Marie-Claire, et al.
Publicado: (2023)

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ugbs8mmit1ud5jd6dgsdv8h9m